Trial Search Results
A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
The purpose of this study is to test whether the combination of IMO2125 with ipilimumab prolongs survival longer than ipilimumab alone in advanced melanoma cancer subjects. IMO-2125 is a synthetic analogue of genetic information; it will be delivered by intratumoral injections to stimulate the immune system to begin recognizing and destroying cancer cells. Ipilimumab is an antibody targeting CTLA-4 and is FDA-approved to treat cancer by activating the subject's immune system to target cancer cells. Investigators believe the combination of IMO-2125 and ipilimumab may increase survival times. Only subjects with metastatic melanoma who have progressed after anti-PD-l treatment are eligible for this study
Stanford is currently not accepting patients for this trial.
Idera Pharmaceuticals, Inc.
Collaborator: Bristol-Myers Squibb
- Drug: Ipilimumab
- Drug: IMO-2125
- Drug: Ipilimumab
1. Subjects must be willing and able to sign the informed consent and comply with the
2. Subjects must be ≥18 years of age.
3. Subjects must have histologically confirmed metastatic melanoma with measurable (by
RECIST v1.1), stage III (lymph node or in transit lesions) or stage IVA, IVB, or IVC
disease that is accessible for injection.
4. Patients must have confirmed progression during or after treatment with a PD-1
inhibitor (cannot be part of a bi-specific antibody) e.g. nivolumab or pembrolizumab.
Confirmed progression is defined as:
- Radiological progression (confirmed at least 4 weeks after the initial scan
showing PD); or
- (For progression based solely on worsening of non-target or new, non-measurable
disease) confirmation by an additional scan at least 4 weeks after the initial
scan unless it is accompanied by correlative symptoms.
In addition, all the following must hold:
1. No intervening anti-cancer therapy between the last course of PD-1 inhibitor
treatment and the first dose of study treatment is allowed except for local
measures (e.g., surgical excision or biopsy, focal radiation therapy).
2. The interval between last PD-1 inhibitor and start of study treatment should be
at least 21 days with no residual anti-PD-1-related immune toxicities in excess
of Grade 1 severity.
3. If BRAF mutation status is unknown, before randomization the subject must have
BRAF testing performed using an approved assay method.
4. Patients with BRAF-positive tumor(s) are eligible for the study if they received
prior treatment with a BRAF inhibitor (alone of in combination with a MEK
inhibitor) or declined targeted therapy.
5. Patients must have Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1.
6. Patients must meet the following laboratory criteria:
1. Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L (1500/mm3)
2. Platelet count ≥ 75 x 10^9/L (75,000/mm3)
3. Hemoglobin ≥ 8.0 g/dL (4.96 mmol/L)
4. Serum creatinine ≤ 1.5 x upper limit of normal (ULN) or calculated creatinine
clearance ≥ 60 mL/minute
5. Aspartate aminotransferase (AST) ≤ 2.5 x ULN; alanine aminotransferase (ALT) ≤
2.5 x ULN; AST/ALT < 5 x ULN if liver involvement
6. Serum bilirubin ≤ 1.5 x ULN, except in subjects with Gilbert's Syndrome who must
have a total bilirubin < 3 mg/dL
7. Women of childbearing potential (WOCBP) and men must agree to use effective
contraceptive methods from Screening throughout the study treatment period and until
at least 90 days after the last dose of either ipilimumab or IMO-2125, whichever is
8. WOCBP must have a negative pregnancy test (serum or urine).
1. Ocular melanoma.
2. Prior therapy with a toll-like receptor (TLR) agonist, excluding topical agents.
3. Prior ipilimumab treatment with the exception of adjuvant treatment completed ≥6
months prior to enrollment
4. Systemic treatment with interferon (IFN)-α within the previous 6 months.
5. Known hypersensitivity to any oligodeoxynucleotide.
6. Active autoimmune disease requiring disease-modifying therapy at the time of
7. Subjects requiring systemic steroid therapy receiving >10 mg/day of prednisone (or
equivalent) for the 2 weeks preceding start of study.
8. Subjects with another primary malignancy that has not been in remission for at least 3
years, with the exception of non-melanoma skin cancer, curatively treated localized
prostate cancer with non-detectable prostate-specific antigen, cervical carcinoma in
situ on biopsy or a squamous intraepithelial lesion on Papanicolaou (Pap) smear, and
thyroid cancer (except anaplastic).
9. Active systemic infections requiring antibiotics
10. Active hepatitis A, B, or C infection.
11. Known diagnosis of human immunodeficiency virus (HIV) infection.
12. Women who are pregnant or breastfeeding.
13. Prior severe reaction to treatment with a human antibody that cannot be managed with
standard supportive measures.
14. Presence of known central nervous system, meningeal, or epidural metastatic disease.
However, subjects with known brain metastases are allowed if the brain metastases are
stable for ≥4 weeks before the first dose of study treatment. Stable is defined as
neurological symptoms not present or resolved to baseline, no radiologic evidence of
progression, and steroid requirement of prednisone ≤10 mg/day or equivalent
15. Impaired cardiac function or clinically significant cardiac disease.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study